JP2000511416A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511416A5
JP2000511416A5 JP1997541828A JP54182897A JP2000511416A5 JP 2000511416 A5 JP2000511416 A5 JP 2000511416A5 JP 1997541828 A JP1997541828 A JP 1997541828A JP 54182897 A JP54182897 A JP 54182897A JP 2000511416 A5 JP2000511416 A5 JP 2000511416A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997541828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511416A (ja
JP4750912B2 (ja
Filing date
Publication date
Priority claimed from GB9610967A external-priority patent/GB9610967D0/en
Application filed filed Critical
Publication of JP2000511416A publication Critical patent/JP2000511416A/ja
Publication of JP2000511416A5 publication Critical patent/JP2000511416A5/ja
Application granted granted Critical
Publication of JP4750912B2 publication Critical patent/JP4750912B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP54182897A 1996-05-24 1997-05-23 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途 Expired - Lifetime JP4750912B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9610967.3 1996-05-24
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods
PCT/GB1997/001412 WO1997045544A1 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008204682A Division JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途

Publications (3)

Publication Number Publication Date
JP2000511416A JP2000511416A (ja) 2000-09-05
JP2000511416A5 true JP2000511416A5 (enExample) 2005-02-10
JP4750912B2 JP4750912B2 (ja) 2011-08-17

Family

ID=10794298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54182897A Expired - Lifetime JP4750912B2 (ja) 1996-05-24 1997-05-23 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途
JP2008204682A Pending JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008204682A Pending JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのｅｄ―ｂドメインに対する抗体、それらの構造及び用途

Country Status (28)

Country Link
US (3) US7273924B1 (enExample)
EP (1) EP0906426B1 (enExample)
JP (2) JP4750912B2 (enExample)
KR (2) KR100741452B1 (enExample)
CN (1) CN100447159C (enExample)
AT (1) ATE361364T1 (enExample)
AU (1) AU729081B2 (enExample)
BG (1) BG65138B1 (enExample)
BR (1) BR9709350B1 (enExample)
CA (1) CA2256308C (enExample)
CZ (1) CZ295531B6 (enExample)
DE (1) DE69737683T2 (enExample)
DK (1) DK0906426T3 (enExample)
EA (1) EA004329B1 (enExample)
ES (1) ES2286831T3 (enExample)
GB (1) GB9610967D0 (enExample)
HU (1) HUP0200546A2 (enExample)
IL (2) IL127216A0 (enExample)
IS (1) IS2508B (enExample)
NO (1) NO324904B1 (enExample)
NZ (1) NZ333083A (enExample)
PL (1) PL188557B1 (enExample)
PT (1) PT906426E (enExample)
SI (1) SI0906426T1 (enExample)
SK (1) SK285916B6 (enExample)
TR (1) TR199802416T2 (enExample)
UA (1) UA74129C2 (enExample)
WO (1) WO1997045544A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2001242432B2 (en) * 2000-02-24 2007-11-08 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1719528B1 (en) 2000-02-24 2011-09-28 Philogen S.p.A. Compositions and methods for treatment of angiogenesis in pathological lesions
CA2411244A1 (en) 2000-05-09 2001-11-15 Greenville Hospital System Therapeutic pore-forming peptides
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
WO2002020563A2 (de) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
EP1461360B1 (en) 2002-01-03 2010-08-18 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
ATE452912T1 (de) * 2002-03-11 2010-01-15 Philogen Spa Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
CN1777621A (zh) 2003-03-14 2006-05-24 Wyeth公司 抗人il－21受体的抗体及其应用
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005280528B2 (en) 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
CN102753569A (zh) 2009-12-14 2012-10-24 塞尔蛋白质股份有限公司 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CA2837804C (en) 2011-06-15 2018-03-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
WO2013186329A1 (en) 2012-06-13 2013-12-19 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
US10611830B2 (en) * 2013-06-06 2020-04-07 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ED-B domain of fibronectin and uses thereof
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
PL3322721T4 (pl) 2015-07-16 2022-06-06 Navigo Proteins Gmbh Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
US20180340936A1 (en) * 2015-11-16 2018-11-29 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
AU2017311541B2 (en) 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
KR102338660B1 (ko) 2016-10-17 2021-12-10 화이자 인코포레이티드 항-edb 항체 및 항체-약물 접합체
WO2018224550A1 (en) 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
US11192943B2 (en) 2017-09-30 2021-12-07 Hefei Lifeon Pharmaceutical Co., Ltd. Protein binding to fibronectin B domain
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
KR20210104106A (ko) 2018-12-18 2021-08-24 나피고 프로타인스 게엠베하 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
KR20220062494A (ko) 2019-08-15 2022-05-17 얀센 바이오테크 인코포레이티드 개선된 단일 사슬 가변 단편을 위한 재료 및 방법
EP4073111A1 (en) 2019-12-11 2022-10-19 Cilag GmbH International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
EP4440599A1 (en) 2022-01-04 2024-10-09 Philogen S.p.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
US20250262307A1 (en) 2022-08-01 2025-08-21 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
CN119816493A (zh) 2022-09-06 2025-04-11 菲罗化学股份公司 用于靶向递送应用的多价成纤维细胞激活蛋白配体
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3650625T2 (de) 1985-01-28 1997-10-02 Xoma Corp AraB-Promoter und Verfahren zur Herstellung von Polypeptiden einschliesslich Cecropinen mittels mikrobiologischer Verfahren
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5243029A (en) 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0311434A3 (en) * 1987-10-09 1990-05-09 The De La Rue Company Plc Integrated circuit card
WO1989006283A1 (en) 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence
IT1217724B (it) * 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) * 1988-09-14 1990-03-15 Fujita Gakuen 抗ｅｄ−ｂ抗体
JPH04169195A (ja) * 1990-10-31 1992-06-17 Fujita Gakuen 抗ｅｄ―ｂモノクローナル抗体
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
EP0614696A4 (en) 1992-09-25 1995-04-26 Otsuka Pharma Co Ltd ADSORBENT FOR CELLULAR FIBRONECTIN, SEPARATION AND PURIFICATION OF FIBRONECTIN, AND PURIFICATION OF BLOOD.
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1719528B1 (en) 2000-02-24 2011-09-28 Philogen S.p.A. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2001242432B2 (en) 2000-02-24 2007-11-08 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1461360B1 (en) 2002-01-03 2010-08-18 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Similar Documents

Publication Publication Date Title
JP2001504330A5 (enExample)
JP2000513471A5 (enExample)
JP2000501018A5 (enExample)
JP2000512783A5 (enExample)
JP2000500076A5 (enExample)
JP2002511159A5 (enExample)
JP2002500504A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2001508473A5 (enExample)
JP2000502472A5 (enExample)
JP2000511416A5 (enExample)
JP2000500874A5 (enExample)
JP2000515132A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2001503620A5 (enExample)
JP2000507828A5 (enExample)
JP2001501936A5 (enExample)
JP2000512095A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)